We have located links that may give you full text access.
Restricted Access: State Medicaid Coverage of Sofosbuvir Hepatitis C Treatment.
Journal of Legal Medicine 2017 January
Chronic hepatitis C (HCV) infection can persist for decades without symptoms. Many Americans are unaware of their infection status and are not receiving necessary care and treatment. This places them at greater risk for severe, even fatal, complications from the disease and increases the likelihood that they will transmit the virus to others. In late 2013, the Food and Drug Administration approved a direct acting antiviral drug called sofosbuvir to treat chronic HCV infection. Sofosbuvir is a highly effective, but very expensive, curative treatment for HCV. Unfortunately, the high price of sofosbuvir has led payers, including Medicaid, to restrict patient access. Looking at the sheer cost of the HCV crisis facing the United States, particularly among minority communities, it is a critical time to invest in prevention, screening, and treatment. These pharmaceutical treatments have the potential to cure HCV, eliminate the virus, and mitigate future health care expenses. This article argues that restricting access to this pharmaceutical treatment may be a discriminatory practice under both Medicaid law and the Affordable Care Act (ACA). In addition to potential legal challenges, there are strong economic and public health imperatives to removing barriers to HCV treatment.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app